相关实验视频

Updated: Sep 11, 2025

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

抗ferroptotic药物减少sFlt-1释放和胎盘损伤在孕前症

Sapir Lianski¹, Tehila Mizrachi¹, Oren Barak^2,3

¹Obstetrics and Gynecology Division, Hadassah Medical Center, Faculty of Medicine of the Hebrew University of Jerusalem, Israel (S.L., T.M., L.T.-M., S.E.-G., S.Y., D.G.-W., S.M.C., O. Beharier).

Hypertension (Dallas, Tex. : 1979)

|August 19, 2025

概括

孕前症涉及胎盘铁亡,这是一个细胞死亡过程,与高可溶性fms类氨酸激酶-1 (sFlt-1) 相关. 药物重定位确定了二皮里达摩尔和普罗梅塔作为潜在的治疗方法,通过抑制铁和降低sFlt-1水平.

科学领域:

产科和妇科产科和妇科
细胞生物学细胞生物学
药理学药理学是指药理学的学科.

背景情况:

孕前是一种妊娠并发症,其特征是高血压,蛋白尿和高抗血管原溶性fms-like-tyrosine kinase-1 (sFlt-1) 水平.
导致sFlt-1失调的精确机制在孕前仍然不完全理解.
这项研究探讨了ferroptosis的作用,一种调节细胞死亡的形式,在先性胎盘病理和sFlt-1释放中.

研究的目的:

为了确定铁致死是否有助于孕前病原和sFlt-1释放.
探索药物重用,以识别针对预先怀孕的铁症的新型治疗剂.

主要方法:

Redox phospholipidomics被用来分析在孕前和健康的胎盘组织中的氧化酸丁乙醇胺.
诱导和抑制胎盘扩张体中的铁化,以评估其对sFlt-1释放的影响.
一个大规模的药物选确定了初级热囊细胞中的铁灭抑制剂.

主要成果:

与对照人群相比,预先胎的胎盘表现出明显更高的氧化酸丁乙醇胺水平.
诱导铁亡会增加sFlt-1的释放,而 Ferrostatin-1 和deferoxamine 的抑制会减少它.
迪皮里达摩尔和普罗梅他被确定为强大的铁灭抑制剂,减少脂质过氧化和sFlt-1释放在先兆子宫前的扩散体.

结论:

胎盘铁是早期妊娠前的一个关键机制,直接与sFlt-1失调有关.
药物重定位确定了具有抗ferroptotic活性的已批准药物作为潜在的孕前治疗药物.
需要进一步的体内研究来确认有效性,并确定这些重新设计的药物的最佳剂量.

关键词:

铁性化 (ferroptosis) 是一种高通量选试验的高通量选试验.胎盘胎盘胎盘胎盘孕产妇产前炎症 (pre-eclampsia) 是一个严重的疾病.sFLT-1蛋白质,人类

更多相关视频

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Published on: November 8, 2024

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Factors Affecting Drug Distribution: Physiological Barriers

Factors Affecting Drug Distribution: Physiological Barriers

Drug distribution in the body is intricately regulated by various physiological barriers that control the passage of substances. These include the capillary endothelial barrier, the blood-brain, blood-cerebrospinal fluid, blood-placental, and blood-testis barriers.
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...

Drug Distribution: Plasma Protein Binding

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...